Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 1.00 |
| ▸ | NAE1 | Q13564 | 3/20 | 1.00 |
| ▸ | UBA3 | Q8TBC4 | 2/20 | 1.00 |
| ▸ | UBA1 | P22314 | 1/20 | 1.00 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 1.00 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 1.00 |
| ▸ | RNMT | O43148 | 1/20 | 0.48 |
| ▸ | ADK | P55263 | 3/20 | 0.46 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18297434 | 1.00 | CA2 (1.00) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL29406144 | 1.00 | CA2 (1.00) | CA2NAE1UBA3UBA1SAE1 | |
| Hydrochloric Acid SCHEMBL18297575 | 0.99 | CA2 (0.99) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL29484015 | 0.94 | CA2 (0.89) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL18297457 | 0.94 | CA2 (0.89) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL18297670 | 0.94 | CA2 (0.88) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL18297530 | 0.92 | CA2 (1.00) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL29484005 | 0.92 | CA2 (1.00) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL18297547 | 0.92 | CA2 (0.85) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL18297439 | 0.92 | CA2 (0.85) | CA2NAE1UBA3UBA1SAE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | IL-2RX | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | TNFRSF9, EGFR, NGFR | CA2 1484/4885NAE1 2987/4885UBA3 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.